Drugs for HER-2-positive Breast Cancer

• Συγγραφή απο Οργανισμό/Αρχή: SpringerLink (Online service)
• Άλλοι συγγραφείς: Sibilia, Maria (Επιμελητής έκδοσης), Zielinski, Christoph C. (Επιμελητής έκδοσης), Bartsch, Rupert (Επιμελητής έκδοσης), Grunt, Thomas W. (Επιμελητής έκδοσης)
• Μορφή: Ηλεκτρονική πηγή Ηλ. βιβλίο
• Γλώσσα: English
• Έκδοση: Basel : Springer Basel, 2011.
• Σειρά: Milestones in Drug Therapy
• Θέματα: Medicine.; Cancer research.; Immunology.; Antibodies.; Pharmacology.; Internal medicine.; Oncology.; Biomedicine.; Pharmacology/Toxicology.; Cancer Research.; Internal Medicine.

Growth factor receptors have long been known to drive malignant transformation and cancer progression. The epidermal growth factor receptor (EGFR, ErbB, HER) system is likely the best described membrane receptor tyrosine kinase family in malignant tumors. With implementation of the growth-inhibitory...

Πίνακας περιεχομένων:

• Drugs for HER-2-positive Breast Cancer: A Major Approval for Translational Cancer Research (Maria Sibilia, Christoph C. Zielinski, Rupert Bartsch, Thomas Grunt)
• The EGFR/ErbB family in breast cancer: from signaling to therapy (Wolfgang J. Köstler and Yosef Yarden)
• Trastuzumab as Adjuvant treatment for early stage HER-2 positive breast cancer (Rupert Bartsch and Guenther G. Steger)
• Trastuzumab Resistance in breast cancer (Floriana Morgillo, Michele Orditura, Teresa Troiani, Erika Martinelli, Ferdinando De Vita, Fortunato Ciardiello)
• Treatment with Trastuzumab beyond Progression (Gunter von Minckwitz and Cristina Pirvulescu)
• Pertuzumab – a HER-2 dimerisation inhibitor – for the treatment of breast and other cancers (Giulia Bianchi and Luca Gianni)
• Beyond trastuzumab: Second generation targeted therapies for HER2--positive breast cancer (Flavio F. Solca, Guenther R. Adolf, Hilary Jones, Martina M. Uttenreuther-Fischer).